Pfizer
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
May 22, 2025Market Access, Research and Development Haematology, Hympavzi, NHS, NICE, Pfizer, haemophilia B, marstacimab
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final …
Pfizer releases results for severe RSV-associated LRTD treatment study
August 13, 2024Clinical Trial Services, Research and Development Immunology, Pfizer, autoimmune, clinical trial, respiratory, vaccines
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical trial into the safety and …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
August 6, 2024Research and Development Cardiac, Cardiology, Pfizer
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. Walton Oaks, 6th August …
Pfizer shares update on DMD gene therapy clinical trial
June 13, 2024Research and Development DMD, Musculo-skeletal disorder, Pfizer, duchenne muscular dystropy, gene therapy
Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, which assessed the investigational mini-dystrophin …
NHS accepts Pfizer’s tafamidis for ATTR-CM treatment
May 14, 2024Medical Communications ATTR-CM, Cardiology, NHS, Pfizer, tafamidis
NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).
Pfizer’s Beqvez approved by FDA for haemophilia B treatment
April 29, 2024Medical Communications FDA, Haematology, Pfizer, haemophilia
Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of …
EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment
April 22, 2024Medical Communications Emblaveo, European Commission, Immunology, Pfizer
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) for the treatment of adult …
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
February 20, 2024Medical Communications European Commission, Gastrointestinal tract, Pfizer, Velsipity, ulcerative colitis
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) in the European Union (EU). …
EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma
December 12, 2023Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma
Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …
CDC Advisory Committee recommends Pfizer’s RSV vaccine
September 25, 2023Medical Communications Abrysvo, Immunology, Pfizer, RSV
Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has …
Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate
September 7, 2023Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease
Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …
FDA approves Pfizer’s vaccine for the prevention of RSV in children
August 22, 2023Research and Development FDA, Paediatrics, Pfizer, RSV
On Monday, Pfizer announced that the US Food and Drug Administration (FDA) has approved Abrysvo for the prevention of respiratory …
FDA grants accelerated approval to Pfizer’s Elrexfio
August 15, 2023Medical Communications Elrexfio, FDA, Oncology, Pfizer, accelerated approval
Pfizer has that the US Food and Drug Administration (FDA) has granted accelerated approval to Elrexfio (elranatamab-bcmm) for the treatment …
AstraZeneca’s Alexion partners with Pfizer for rare disease therapies
July 28, 2023Research and Development Alexion, AstraZeneca, Pfizer, Rare Diseases, genomics, rare disease
Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and licence agreement with Pfizer. The …
Pfizer shares new data from phase 2 trial for GBS maternal vaccine candidate
July 20, 2023Research and Development Immunology, Pfizer, Vaccine, clinical trial
Pfizer has announced new data from its phase 2 study which assessed its hexavalent capsular polysaccharide (CPS) conjugate Group B …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
